nodes	percent_of_prediction	percent_of_DWPC	metapath
Apixaban—ABCB1—Mitomycin—urinary bladder cancer	0.0889	0.127	CbGbCtD
Apixaban—ABCG2—Fluorouracil—urinary bladder cancer	0.0607	0.0866	CbGbCtD
Apixaban—ABCG2—Carboplatin—urinary bladder cancer	0.0604	0.0861	CbGbCtD
Apixaban—ABCG2—Cisplatin—urinary bladder cancer	0.0516	0.0736	CbGbCtD
Apixaban—ABCG2—Etoposide—urinary bladder cancer	0.0507	0.0723	CbGbCtD
Apixaban—CYP3A4—Thiotepa—urinary bladder cancer	0.0404	0.0576	CbGbCtD
Apixaban—ABCG2—Doxorubicin—urinary bladder cancer	0.0346	0.0493	CbGbCtD
Apixaban—ABCG2—Methotrexate—urinary bladder cancer	0.0335	0.0478	CbGbCtD
Apixaban—CYP2C8—Fluorouracil—urinary bladder cancer	0.0323	0.0461	CbGbCtD
Apixaban—CYP3A5—Etoposide—urinary bladder cancer	0.0281	0.04	CbGbCtD
Apixaban—CYP2C8—Etoposide—urinary bladder cancer	0.027	0.0385	CbGbCtD
Apixaban—ABCB1—Gemcitabine—urinary bladder cancer	0.0256	0.0365	CbGbCtD
Apixaban—CYP1A2—Fluorouracil—urinary bladder cancer	0.025	0.0357	CbGbCtD
Apixaban—CYP2C9—Fluorouracil—urinary bladder cancer	0.0226	0.0322	CbGbCtD
Apixaban—CYP1A2—Etoposide—urinary bladder cancer	0.0209	0.0298	CbGbCtD
Apixaban—CYP2C9—Cisplatin—urinary bladder cancer	0.0192	0.0273	CbGbCtD
Apixaban—ABCB1—Cisplatin—urinary bladder cancer	0.0186	0.0265	CbGbCtD
Apixaban—ABCB1—Etoposide—urinary bladder cancer	0.0183	0.0261	CbGbCtD
Apixaban—ABCB1—Doxorubicin—urinary bladder cancer	0.0125	0.0178	CbGbCtD
Apixaban—ABCB1—Methotrexate—urinary bladder cancer	0.0121	0.0172	CbGbCtD
Apixaban—CYP3A4—Etoposide—urinary bladder cancer	0.0109	0.0156	CbGbCtD
Apixaban—CYP3A4—Doxorubicin—urinary bladder cancer	0.00747	0.0106	CbGbCtD
Apixaban—CYP2C19—urine—urinary bladder cancer	0.00525	0.0866	CbGeAlD
Apixaban—F10—prostate gland—urinary bladder cancer	0.00515	0.0849	CbGeAlD
Apixaban—CYP1A2—urine—urinary bladder cancer	0.00429	0.0707	CbGeAlD
Apixaban—CYP2J2—prostate gland—urinary bladder cancer	0.00422	0.0696	CbGeAlD
Apixaban—CYP2C9—urine—urinary bladder cancer	0.00407	0.0672	CbGeAlD
Apixaban—F10—urethra—urinary bladder cancer	0.00345	0.0569	CbGeAlD
Apixaban—CYP3A4—urine—urinary bladder cancer	0.00311	0.0512	CbGeAlD
Apixaban—F10—female reproductive system—urinary bladder cancer	0.00281	0.0464	CbGeAlD
Apixaban—F10—vagina—urinary bladder cancer	0.00254	0.0419	CbGeAlD
Apixaban—CYP2J2—female reproductive system—urinary bladder cancer	0.0023	0.038	CbGeAlD
Apixaban—CYP2J2—vagina—urinary bladder cancer	0.00208	0.0344	CbGeAlD
Apixaban—F10—lymph node—urinary bladder cancer	0.00164	0.0271	CbGeAlD
Apixaban—ABCG2—prostate gland—urinary bladder cancer	0.0016	0.0264	CbGeAlD
Apixaban—CYP3A5—prostate gland—urinary bladder cancer	0.00149	0.0245	CbGeAlD
Apixaban—ABCG2—seminal vesicle—urinary bladder cancer	0.00135	0.0223	CbGeAlD
Apixaban—CYP2C8—renal system—urinary bladder cancer	0.00112	0.0185	CbGeAlD
Apixaban—Petechiae—Gemcitabine—urinary bladder cancer	0.00109	0.0106	CcSEcCtD
Apixaban—ABCG2—urethra—urinary bladder cancer	0.00107	0.0177	CbGeAlD
Apixaban—Drug hypersensitivity—Epirubicin—urinary bladder cancer	0.00107	0.0104	CcSEcCtD
Apixaban—Haematochezia—Epirubicin—urinary bladder cancer	0.00107	0.0104	CcSEcCtD
Apixaban—CYP1A2—renal system—urinary bladder cancer	0.00105	0.0173	CbGeAlD
Apixaban—CYP3A5—renal system—urinary bladder cancer	0.00101	0.0167	CbGeAlD
Apixaban—Haematochezia—Doxorubicin—urinary bladder cancer	0.000987	0.00963	CcSEcCtD
Apixaban—Drug hypersensitivity—Doxorubicin—urinary bladder cancer	0.000987	0.00963	CcSEcCtD
Apixaban—Blood bilirubin increased—Gemcitabine—urinary bladder cancer	0.000949	0.00926	CcSEcCtD
Apixaban—CYP2C19—vagina—urinary bladder cancer	0.000931	0.0154	CbGeAlD
Apixaban—CYP2C8—female reproductive system—urinary bladder cancer	0.000899	0.0148	CbGeAlD
Apixaban—Blood alkaline phosphatase increased—Thiotepa—urinary bladder cancer	0.000891	0.00869	CcSEcCtD
Apixaban—Anaemia—Mitomycin—urinary bladder cancer	0.000858	0.00837	CcSEcCtD
Apixaban—Syncope—Mitomycin—urinary bladder cancer	0.000832	0.00812	CcSEcCtD
Apixaban—Loss of consciousness—Mitomycin—urinary bladder cancer	0.000816	0.00796	CcSEcCtD
Apixaban—CYP2C8—vagina—urinary bladder cancer	0.000813	0.0134	CbGeAlD
Apixaban—CYP2C9—female reproductive system—urinary bladder cancer	0.000798	0.0132	CbGeAlD
Apixaban—ABCG2—vagina—urinary bladder cancer	0.00079	0.013	CbGeAlD
Apixaban—ABCB1—prostate gland—urinary bladder cancer	0.000789	0.013	CbGeAlD
Apixaban—CYP3A4—renal system—urinary bladder cancer	0.00076	0.0125	CbGeAlD
Apixaban—Gingival bleeding—Epirubicin—urinary bladder cancer	0.000757	0.00739	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Gemcitabine—urinary bladder cancer	0.000749	0.00731	CcSEcCtD
Apixaban—Shock—Mitomycin—urinary bladder cancer	0.000745	0.00727	CcSEcCtD
Apixaban—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.000741	0.00723	CcSEcCtD
Apixaban—CYP3A5—vagina—urinary bladder cancer	0.000733	0.0121	CbGeAlD
Apixaban—Dizziness—Valrubicin—urinary bladder cancer	0.000727	0.00709	CcSEcCtD
Apixaban—Transaminases increased—Epirubicin—urinary bladder cancer	0.000707	0.00689	CcSEcCtD
Apixaban—Gingival bleeding—Doxorubicin—urinary bladder cancer	0.000701	0.00684	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Thiotepa—urinary bladder cancer	0.000698	0.00681	CcSEcCtD
Apixaban—Rash—Valrubicin—urinary bladder cancer	0.000693	0.00676	CcSEcCtD
Apixaban—Dermatitis—Valrubicin—urinary bladder cancer	0.000692	0.00676	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Thiotepa—urinary bladder cancer	0.000683	0.00667	CcSEcCtD
Apixaban—ABCB1—seminal vesicle—urinary bladder cancer	0.000668	0.011	CbGeAlD
Apixaban—Haematemesis—Methotrexate—urinary bladder cancer	0.000661	0.00645	CcSEcCtD
Apixaban—Transaminases increased—Doxorubicin—urinary bladder cancer	0.000654	0.00638	CcSEcCtD
Apixaban—Nausea—Valrubicin—urinary bladder cancer	0.000653	0.00637	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Fluorouracil—urinary bladder cancer	0.000641	0.00625	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Etoposide—urinary bladder cancer	0.00064	0.00624	CcSEcCtD
Apixaban—Haematemesis—Epirubicin—urinary bladder cancer	0.000619	0.00604	CcSEcCtD
Apixaban—CYP3A4—female reproductive system—urinary bladder cancer	0.000609	0.01	CbGeAlD
Apixaban—Gastrointestinal haemorrhage—Cisplatin—urinary bladder cancer	0.000608	0.00593	CcSEcCtD
Apixaban—Liver function test abnormal—Gemcitabine—urinary bladder cancer	0.000602	0.00587	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Gemcitabine—urinary bladder cancer	0.000587	0.00573	CcSEcCtD
Apixaban—Vaginal haemorrhage—Epirubicin—urinary bladder cancer	0.000581	0.00567	CcSEcCtD
Apixaban—Haemoptysis—Epirubicin—urinary bladder cancer	0.000581	0.00567	CcSEcCtD
Apixaban—ABCB1—epithelium—urinary bladder cancer	0.00058	0.00956	CbGeAlD
Apixaban—Alanine aminotransferase increased—Gemcitabine—urinary bladder cancer	0.000575	0.00561	CcSEcCtD
Apixaban—Haematemesis—Doxorubicin—urinary bladder cancer	0.000572	0.00558	CcSEcCtD
Apixaban—Haematuria—Thiotepa—urinary bladder cancer	0.000569	0.00555	CcSEcCtD
Apixaban—Hepatobiliary disease—Thiotepa—urinary bladder cancer	0.000565	0.00551	CcSEcCtD
Apixaban—Epistaxis—Thiotepa—urinary bladder cancer	0.000563	0.0055	CcSEcCtD
Apixaban—Petechiae—Methotrexate—urinary bladder cancer	0.000558	0.00545	CcSEcCtD
Apixaban—Breast disorder—Cisplatin—urinary bladder cancer	0.000549	0.00536	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Cisplatin—urinary bladder cancer	0.000547	0.00534	CcSEcCtD
Apixaban—Haemoglobin—Thiotepa—urinary bladder cancer	0.000539	0.00526	CcSEcCtD
Apixaban—ABCB1—renal system—urinary bladder cancer	0.000538	0.00887	CbGeAlD
Apixaban—Vaginal haemorrhage—Doxorubicin—urinary bladder cancer	0.000537	0.00524	CcSEcCtD
Apixaban—Haemoptysis—Doxorubicin—urinary bladder cancer	0.000537	0.00524	CcSEcCtD
Apixaban—Haemorrhage—Thiotepa—urinary bladder cancer	0.000536	0.00523	CcSEcCtD
Apixaban—Urinary tract disorder—Thiotepa—urinary bladder cancer	0.000529	0.00516	CcSEcCtD
Apixaban—ABCB1—urethra—urinary bladder cancer	0.000528	0.00871	CbGeAlD
Apixaban—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.000527	0.00514	CcSEcCtD
Apixaban—Urethral disorder—Thiotepa—urinary bladder cancer	0.000525	0.00513	CcSEcCtD
Apixaban—Petechiae—Epirubicin—urinary bladder cancer	0.000522	0.0051	CcSEcCtD
Apixaban—ABCG2—lymph node—urinary bladder cancer	0.000511	0.00843	CbGeAlD
Apixaban—Eye disorder—Thiotepa—urinary bladder cancer	0.000501	0.00489	CcSEcCtD
Apixaban—Dizziness—Mitomycin—urinary bladder cancer	0.000501	0.00489	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Etoposide—urinary bladder cancer	0.000491	0.00479	CcSEcCtD
Apixaban—Angiopathy—Thiotepa—urinary bladder cancer	0.000486	0.00475	CcSEcCtD
Apixaban—Immune system disorder—Thiotepa—urinary bladder cancer	0.000484	0.00472	CcSEcCtD
Apixaban—Petechiae—Doxorubicin—urinary bladder cancer	0.000483	0.00472	CcSEcCtD
Apixaban—Mediastinal disorder—Thiotepa—urinary bladder cancer	0.000483	0.00471	CcSEcCtD
Apixaban—Haematuria—Gemcitabine—urinary bladder cancer	0.000479	0.00467	CcSEcCtD
Apixaban—Rash—Mitomycin—urinary bladder cancer	0.000477	0.00466	CcSEcCtD
Apixaban—Dermatitis—Mitomycin—urinary bladder cancer	0.000477	0.00465	CcSEcCtD
Apixaban—Rectal haemorrhage—Epirubicin—urinary bladder cancer	0.000476	0.00464	CcSEcCtD
Apixaban—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.000475	0.00464	CcSEcCtD
Apixaban—Epistaxis—Fluorouracil—urinary bladder cancer	0.000466	0.00455	CcSEcCtD
Apixaban—Blood bilirubin increased—Epirubicin—urinary bladder cancer	0.000454	0.00443	CcSEcCtD
Apixaban—Haemoglobin—Gemcitabine—urinary bladder cancer	0.000453	0.00442	CcSEcCtD
Apixaban—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000451	0.0044	CcSEcCtD
Apixaban—Nausea—Mitomycin—urinary bladder cancer	0.00045	0.00439	CcSEcCtD
Apixaban—Melaena—Methotrexate—urinary bladder cancer	0.000449	0.00438	CcSEcCtD
Apixaban—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000446	0.00435	CcSEcCtD
Apixaban—Urinary tract disorder—Gemcitabine—urinary bladder cancer	0.000445	0.00434	CcSEcCtD
Apixaban—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000443	0.00433	CcSEcCtD
Apixaban—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000443	0.00432	CcSEcCtD
Apixaban—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.000443	0.00432	CcSEcCtD
Apixaban—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000442	0.00431	CcSEcCtD
Apixaban—Rectal haemorrhage—Doxorubicin—urinary bladder cancer	0.00044	0.0043	CcSEcCtD
Apixaban—Anaemia—Thiotepa—urinary bladder cancer	0.000431	0.00421	CcSEcCtD
Apixaban—ABCB1—female reproductive system—urinary bladder cancer	0.000431	0.0071	CbGeAlD
Apixaban—Blood bilirubin increased—Doxorubicin—urinary bladder cancer	0.00042	0.0041	CcSEcCtD
Apixaban—Melaena—Epirubicin—urinary bladder cancer	0.00042	0.0041	CcSEcCtD
Apixaban—Ecchymosis—Methotrexate—urinary bladder cancer	0.000415	0.00405	CcSEcCtD
Apixaban—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000415	0.00405	CcSEcCtD
Apixaban—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000413	0.00403	CcSEcCtD
Apixaban—Urethral disorder—Cisplatin—urinary bladder cancer	0.000412	0.00402	CcSEcCtD
Apixaban—Angiopathy—Gemcitabine—urinary bladder cancer	0.000409	0.00399	CcSEcCtD
Apixaban—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000407	0.00397	CcSEcCtD
Apixaban—Mediastinal disorder—Gemcitabine—urinary bladder cancer	0.000406	0.00397	CcSEcCtD
Apixaban—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000406	0.00396	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000395	0.00385	CcSEcCtD
Apixaban—Eye disorder—Cisplatin—urinary bladder cancer	0.000393	0.00383	CcSEcCtD
Apixaban—ABCB1—vagina—urinary bladder cancer	0.00039	0.00642	CbGeAlD
Apixaban—Ecchymosis—Epirubicin—urinary bladder cancer	0.000389	0.00379	CcSEcCtD
Apixaban—Melaena—Doxorubicin—urinary bladder cancer	0.000388	0.00379	CcSEcCtD
Apixaban—Diabetes mellitus—Methotrexate—urinary bladder cancer	0.000383	0.00374	CcSEcCtD
Apixaban—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00038	0.00371	CcSEcCtD
Apixaban—Immune system disorder—Cisplatin—urinary bladder cancer	0.00038	0.0037	CcSEcCtD
Apixaban—Mediastinal disorder—Cisplatin—urinary bladder cancer	0.000379	0.0037	CcSEcCtD
Apixaban—Urethral disorder—Etoposide—urinary bladder cancer	0.000377	0.00368	CcSEcCtD
Apixaban—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000373	0.00364	CcSEcCtD
Apixaban—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000373	0.00364	CcSEcCtD
Apixaban—Skin disorder—Thiotepa—urinary bladder cancer	0.00037	0.00361	CcSEcCtD
Apixaban—Anaemia—Gemcitabine—urinary bladder cancer	0.000363	0.00354	CcSEcCtD
Apixaban—Eye disorder—Etoposide—urinary bladder cancer	0.00036	0.00351	CcSEcCtD
Apixaban—Ecchymosis—Doxorubicin—urinary bladder cancer	0.00036	0.00351	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Epirubicin—urinary bladder cancer	0.000359	0.0035	CcSEcCtD
Apixaban—Diabetes mellitus—Epirubicin—urinary bladder cancer	0.000359	0.0035	CcSEcCtD
Apixaban—Anaemia—Fluorouracil—urinary bladder cancer	0.000357	0.00348	CcSEcCtD
Apixaban—Angiopathy—Etoposide—urinary bladder cancer	0.000349	0.00341	CcSEcCtD
Apixaban—Immune system disorder—Etoposide—urinary bladder cancer	0.000348	0.00339	CcSEcCtD
Apixaban—Mediastinal disorder—Etoposide—urinary bladder cancer	0.000347	0.00339	CcSEcCtD
Apixaban—Anaemia—Cisplatin—urinary bladder cancer	0.000338	0.0033	CcSEcCtD
Apixaban—Blood alkaline phosphatase increased—Doxorubicin—urinary bladder cancer	0.000332	0.00324	CcSEcCtD
Apixaban—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.000332	0.00324	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000332	0.00324	CcSEcCtD
Apixaban—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000329	0.00321	CcSEcCtD
Apixaban—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00032	0.00313	CcSEcCtD
Apixaban—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000315	0.00307	CcSEcCtD
Apixaban—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000314	0.00307	CcSEcCtD
Apixaban—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000314	0.00306	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Epirubicin—urinary bladder cancer	0.000312	0.00304	CcSEcCtD
Apixaban—Skin disorder—Gemcitabine—urinary bladder cancer	0.000311	0.00304	CcSEcCtD
Apixaban—Anaemia—Etoposide—urinary bladder cancer	0.00031	0.00302	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000309	0.00302	CcSEcCtD
Apixaban—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000309	0.00301	CcSEcCtD
Apixaban—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000308	0.00301	CcSEcCtD
Apixaban—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000308	0.003	CcSEcCtD
Apixaban—Breast disorder—Methotrexate—urinary bladder cancer	0.000301	0.00294	CcSEcCtD
Apixaban—Hypotension—Gemcitabine—urinary bladder cancer	0.000299	0.00292	CcSEcCtD
Apixaban—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000299	0.00291	CcSEcCtD
Apixaban—Loss of consciousness—Etoposide—urinary bladder cancer	0.000295	0.00287	CcSEcCtD
Apixaban—Hypotension—Fluorouracil—urinary bladder cancer	0.000294	0.00287	CcSEcCtD
Apixaban—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000293	0.00286	CcSEcCtD
Apixaban—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000292	0.00285	CcSEcCtD
Apixaban—Skin disorder—Cisplatin—urinary bladder cancer	0.00029	0.00283	CcSEcCtD
Apixaban—Gastrointestinal haemorrhage—Doxorubicin—urinary bladder cancer	0.000289	0.00282	CcSEcCtD
Apixaban—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000288	0.00281	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000283	0.00277	CcSEcCtD
Apixaban—Breast disorder—Epirubicin—urinary bladder cancer	0.000282	0.00275	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000281	0.00274	CcSEcCtD
Apixaban—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000281	0.00274	CcSEcCtD
Apixaban—Hypotension—Cisplatin—urinary bladder cancer	0.000279	0.00272	CcSEcCtD
Apixaban—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000277	0.0027	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000275	0.00268	CcSEcCtD
Apixaban—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000274	0.00267	CcSEcCtD
Apixaban—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000272	0.00265	CcSEcCtD
Apixaban—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000268	0.00261	CcSEcCtD
Apixaban—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000267	0.0026	CcSEcCtD
Apixaban—Skin disorder—Etoposide—urinary bladder cancer	0.000266	0.00259	CcSEcCtD
Apixaban—Breast disorder—Doxorubicin—urinary bladder cancer	0.000261	0.00255	CcSEcCtD
Apixaban—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.00026	0.00254	CcSEcCtD
Apixaban—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000258	0.00252	CcSEcCtD
Apixaban—Hypotension—Etoposide—urinary bladder cancer	0.000256	0.00249	CcSEcCtD
Apixaban—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000255	0.00248	CcSEcCtD
Apixaban—ABCB1—lymph node—urinary bladder cancer	0.000252	0.00416	CbGeAlD
Apixaban—Dizziness—Thiotepa—urinary bladder cancer	0.000252	0.00246	CcSEcCtD
Apixaban—Haematuria—Methotrexate—urinary bladder cancer	0.000245	0.00239	CcSEcCtD
Apixaban—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000243	0.00237	CcSEcCtD
Apixaban—Epistaxis—Methotrexate—urinary bladder cancer	0.000242	0.00236	CcSEcCtD
Apixaban—Rash—Thiotepa—urinary bladder cancer	0.00024	0.00234	CcSEcCtD
Apixaban—Dermatitis—Thiotepa—urinary bladder cancer	0.00024	0.00234	CcSEcCtD
Apixaban—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000236	0.0023	CcSEcCtD
Apixaban—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000232	0.00226	CcSEcCtD
Apixaban—Haemoglobin—Methotrexate—urinary bladder cancer	0.000232	0.00226	CcSEcCtD
Apixaban—Haemorrhage—Methotrexate—urinary bladder cancer	0.000231	0.00225	CcSEcCtD
Apixaban—Haematuria—Epirubicin—urinary bladder cancer	0.000229	0.00224	CcSEcCtD
Apixaban—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000228	0.00222	CcSEcCtD
Apixaban—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000227	0.00222	CcSEcCtD
Apixaban—Epistaxis—Epirubicin—urinary bladder cancer	0.000227	0.00221	CcSEcCtD
Apixaban—Nausea—Thiotepa—urinary bladder cancer	0.000226	0.00221	CcSEcCtD
Apixaban—Urethral disorder—Methotrexate—urinary bladder cancer	0.000226	0.00221	CcSEcCtD
Apixaban—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00022	0.00215	CcSEcCtD
Apixaban—Haemoglobin—Epirubicin—urinary bladder cancer	0.000217	0.00212	CcSEcCtD
Apixaban—Haemorrhage—Epirubicin—urinary bladder cancer	0.000216	0.00211	CcSEcCtD
Apixaban—Eye disorder—Methotrexate—urinary bladder cancer	0.000216	0.0021	CcSEcCtD
Apixaban—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000213	0.00208	CcSEcCtD
Apixaban—Haematuria—Doxorubicin—urinary bladder cancer	0.000212	0.00207	CcSEcCtD
Apixaban—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000212	0.00207	CcSEcCtD
Apixaban—Urethral disorder—Epirubicin—urinary bladder cancer	0.000212	0.00206	CcSEcCtD
Apixaban—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.00021	0.00205	CcSEcCtD
Apixaban—Epistaxis—Doxorubicin—urinary bladder cancer	0.00021	0.00205	CcSEcCtD
Apixaban—Angiopathy—Methotrexate—urinary bladder cancer	0.000209	0.00204	CcSEcCtD
Apixaban—Immune system disorder—Methotrexate—urinary bladder cancer	0.000208	0.00203	CcSEcCtD
Apixaban—Dizziness—Fluorouracil—urinary bladder cancer	0.000208	0.00203	CcSEcCtD
Apixaban—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000208	0.00203	CcSEcCtD
Apixaban—Rash—Gemcitabine—urinary bladder cancer	0.000202	0.00197	CcSEcCtD
Apixaban—Dermatitis—Gemcitabine—urinary bladder cancer	0.000202	0.00197	CcSEcCtD
Apixaban—Eye disorder—Epirubicin—urinary bladder cancer	0.000202	0.00197	CcSEcCtD
Apixaban—Hypersensitivity—Etoposide—urinary bladder cancer	0.000202	0.00197	CcSEcCtD
Apixaban—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000201	0.00196	CcSEcCtD
Apixaban—Haemorrhage—Doxorubicin—urinary bladder cancer	0.0002	0.00195	CcSEcCtD
Apixaban—Rash—Fluorouracil—urinary bladder cancer	0.000199	0.00194	CcSEcCtD
Apixaban—Dermatitis—Fluorouracil—urinary bladder cancer	0.000198	0.00194	CcSEcCtD
Apixaban—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000197	0.00192	CcSEcCtD
Apixaban—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000196	0.00191	CcSEcCtD
Apixaban—Angiopathy—Epirubicin—urinary bladder cancer	0.000196	0.00191	CcSEcCtD
Apixaban—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000196	0.00191	CcSEcCtD
Apixaban—Immune system disorder—Epirubicin—urinary bladder cancer	0.000195	0.0019	CcSEcCtD
Apixaban—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000195	0.0019	CcSEcCtD
Apixaban—Nausea—Gemcitabine—urinary bladder cancer	0.00019	0.00186	CcSEcCtD
Apixaban—Rash—Cisplatin—urinary bladder cancer	0.000188	0.00184	CcSEcCtD
Apixaban—Dermatitis—Cisplatin—urinary bladder cancer	0.000188	0.00184	CcSEcCtD
Apixaban—Nausea—Fluorouracil—urinary bladder cancer	0.000187	0.00183	CcSEcCtD
Apixaban—Eye disorder—Doxorubicin—urinary bladder cancer	0.000187	0.00182	CcSEcCtD
Apixaban—Anaemia—Methotrexate—urinary bladder cancer	0.000186	0.00181	CcSEcCtD
Apixaban—Angiopathy—Doxorubicin—urinary bladder cancer	0.000181	0.00177	CcSEcCtD
Apixaban—Dizziness—Etoposide—urinary bladder cancer	0.000181	0.00176	CcSEcCtD
Apixaban—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00018	0.00176	CcSEcCtD
Apixaban—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.00018	0.00176	CcSEcCtD
Apixaban—Nausea—Cisplatin—urinary bladder cancer	0.000177	0.00173	CcSEcCtD
Apixaban—Anaemia—Epirubicin—urinary bladder cancer	0.000174	0.00169	CcSEcCtD
Apixaban—Rash—Etoposide—urinary bladder cancer	0.000172	0.00168	CcSEcCtD
Apixaban—Dermatitis—Etoposide—urinary bladder cancer	0.000172	0.00168	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00017	0.00166	CcSEcCtD
Apixaban—Syncope—Epirubicin—urinary bladder cancer	0.000169	0.00164	CcSEcCtD
Apixaban—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000165	0.00161	CcSEcCtD
Apixaban—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000164	0.0016	CcSEcCtD
Apixaban—Nausea—Etoposide—urinary bladder cancer	0.000162	0.00159	CcSEcCtD
Apixaban—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000161	0.00157	CcSEcCtD
Apixaban—Anaemia—Doxorubicin—urinary bladder cancer	0.000161	0.00157	CcSEcCtD
Apixaban—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.00016	0.00157	CcSEcCtD
Apixaban—Skin disorder—Methotrexate—urinary bladder cancer	0.000159	0.00155	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000159	0.00155	CcSEcCtD
Apixaban—Syncope—Doxorubicin—urinary bladder cancer	0.000156	0.00152	CcSEcCtD
Apixaban—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000153	0.0015	CcSEcCtD
Apixaban—Hypotension—Methotrexate—urinary bladder cancer	0.000153	0.00149	CcSEcCtD
Apixaban—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000153	0.00149	CcSEcCtD
Apixaban—Shock—Epirubicin—urinary bladder cancer	0.000151	0.00147	CcSEcCtD
Apixaban—Nervous system disorder—Epirubicin—urinary bladder cancer	0.00015	0.00147	CcSEcCtD
Apixaban—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00015	0.00146	CcSEcCtD
Apixaban—Skin disorder—Epirubicin—urinary bladder cancer	0.000149	0.00145	CcSEcCtD
Apixaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000147	0.00143	CcSEcCtD
Apixaban—Hypotension—Epirubicin—urinary bladder cancer	0.000143	0.0014	CcSEcCtD
Apixaban—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000142	0.00138	CcSEcCtD
Apixaban—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000141	0.00138	CcSEcCtD
Apixaban—Shock—Doxorubicin—urinary bladder cancer	0.00014	0.00136	CcSEcCtD
Apixaban—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000139	0.00136	CcSEcCtD
Apixaban—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000139	0.00136	CcSEcCtD
Apixaban—Skin disorder—Doxorubicin—urinary bladder cancer	0.000138	0.00134	CcSEcCtD
Apixaban—Hypotension—Doxorubicin—urinary bladder cancer	0.000133	0.00129	CcSEcCtD
Apixaban—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000132	0.00129	CcSEcCtD
Apixaban—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000122	0.0012	CcSEcCtD
Apixaban—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000121	0.00118	CcSEcCtD
Apixaban—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000113	0.0011	CcSEcCtD
Apixaban—Dizziness—Methotrexate—urinary bladder cancer	0.000108	0.00106	CcSEcCtD
Apixaban—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000105	0.00102	CcSEcCtD
Apixaban—Rash—Methotrexate—urinary bladder cancer	0.000103	0.00101	CcSEcCtD
Apixaban—Dermatitis—Methotrexate—urinary bladder cancer	0.000103	0.00101	CcSEcCtD
Apixaban—Dizziness—Epirubicin—urinary bladder cancer	0.000101	0.000989	CcSEcCtD
Apixaban—Nausea—Methotrexate—urinary bladder cancer	9.73e-05	0.00095	CcSEcCtD
Apixaban—Rash—Epirubicin—urinary bladder cancer	9.67e-05	0.000943	CcSEcCtD
Apixaban—Dermatitis—Epirubicin—urinary bladder cancer	9.66e-05	0.000942	CcSEcCtD
Apixaban—Dizziness—Doxorubicin—urinary bladder cancer	9.38e-05	0.000915	CcSEcCtD
Apixaban—Nausea—Epirubicin—urinary bladder cancer	9.11e-05	0.000889	CcSEcCtD
Apixaban—Rash—Doxorubicin—urinary bladder cancer	8.95e-05	0.000873	CcSEcCtD
Apixaban—Dermatitis—Doxorubicin—urinary bladder cancer	8.94e-05	0.000872	CcSEcCtD
Apixaban—Nausea—Doxorubicin—urinary bladder cancer	8.43e-05	0.000822	CcSEcCtD
Apixaban—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	4.83e-05	0.000356	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	4.8e-05	0.000354	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	4.78e-05	0.000353	CbGpPWpGaD
Apixaban—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.77e-05	0.000351	CbGpPWpGaD
Apixaban—F10—Hemostasis—TP53—urinary bladder cancer	4.76e-05	0.000351	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	4.69e-05	0.000346	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	4.67e-05	0.000344	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NAT1—urinary bladder cancer	4.67e-05	0.000344	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—NAT2—urinary bladder cancer	4.62e-05	0.00034	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.59e-05	0.000339	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	4.57e-05	0.000337	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	4.56e-05	0.000337	CbGpPWpGaD
Apixaban—F10—Hemostasis—HRAS—urinary bladder cancer	4.56e-05	0.000336	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTO2—urinary bladder cancer	4.55e-05	0.000336	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NAT1—urinary bladder cancer	4.55e-05	0.000336	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	4.51e-05	0.000332	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	4.49e-05	0.000331	CbGpPWpGaD
Apixaban—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.44e-05	0.000328	CbGpPWpGaD
Apixaban—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.38e-05	0.000323	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	4.31e-05	0.000318	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	4.27e-05	0.000315	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NAT1—urinary bladder cancer	4.26e-05	0.000314	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	4.26e-05	0.000314	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.19e-05	0.000309	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	4.17e-05	0.000307	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	4.07e-05	0.0003	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—PPARG—urinary bladder cancer	4.06e-05	0.0003	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—RRM2—urinary bladder cancer	3.98e-05	0.000294	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	3.96e-05	0.000292	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—CREBBP—urinary bladder cancer	3.9e-05	0.000288	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	3.89e-05	0.000287	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	3.87e-05	0.000286	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	3.84e-05	0.000283	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	3.84e-05	0.000283	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	3.82e-05	0.000282	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	3.75e-05	0.000277	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	3.74e-05	0.000276	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—HPGDS—urinary bladder cancer	3.69e-05	0.000272	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—ENO2—urinary bladder cancer	3.69e-05	0.000272	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—TYMP—urinary bladder cancer	3.66e-05	0.00027	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	3.64e-05	0.000268	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NAT1—urinary bladder cancer	3.64e-05	0.000268	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	3.63e-05	0.000268	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—GSTT1—urinary bladder cancer	3.58e-05	0.000264	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	3.58e-05	0.000264	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.54e-05	0.000261	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	3.54e-05	0.000261	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	3.5e-05	0.000258	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.45e-05	0.000255	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.38e-05	0.000249	CbGpPWpGaD
Apixaban—ABCG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.35e-05	0.000247	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	3.33e-05	0.000245	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	3.31e-05	0.000244	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—NAT2—urinary bladder cancer	3.31e-05	0.000244	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.27e-05	0.000241	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.26e-05	0.00024	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	3.22e-05	0.000238	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—PTGS2—urinary bladder cancer	3.2e-05	0.000236	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.18e-05	0.000234	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—TYMP—urinary bladder cancer	3.17e-05	0.000234	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.11e-05	0.000229	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.04e-05	0.000224	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.02e-05	0.000223	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	2.99e-05	0.000221	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—NQO1—urinary bladder cancer	2.97e-05	0.000219	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	2.96e-05	0.000218	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—NAT2—urinary bladder cancer	2.86e-05	0.000211	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—RRM2—urinary bladder cancer	2.85e-05	0.000211	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.84e-05	0.000209	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.83e-05	0.000209	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—TYMP—urinary bladder cancer	2.83e-05	0.000209	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	2.81e-05	0.000207	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NAT1—urinary bladder cancer	2.81e-05	0.000207	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—PTEN—urinary bladder cancer	2.79e-05	0.000206	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.76e-05	0.000204	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	2.76e-05	0.000203	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.72e-05	0.0002	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.71e-05	0.0002	CbGpPWpGaD
Apixaban—CYP2J2—Metabolism—EP300—urinary bladder cancer	2.66e-05	0.000196	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.65e-05	0.000195	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.64e-05	0.000195	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.64e-05	0.000195	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.59e-05	0.000191	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—TYMP—urinary bladder cancer	2.58e-05	0.00019	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.57e-05	0.000189	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.56e-05	0.000189	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.56e-05	0.000189	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.52e-05	0.000186	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.5e-05	0.000185	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.5e-05	0.000184	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—GSTP1—urinary bladder cancer	2.48e-05	0.000183	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.48e-05	0.000183	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—RRM2—urinary bladder cancer	2.47e-05	0.000182	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NAT2—urinary bladder cancer	2.33e-05	0.000172	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.31e-05	0.00017	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—TYMS—urinary bladder cancer	2.31e-05	0.00017	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—ENO2—urinary bladder cancer	2.29e-05	0.000169	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	2.29e-05	0.000169	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—GSTM1—urinary bladder cancer	2.28e-05	0.000168	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—NCOR1—urinary bladder cancer	2.28e-05	0.000168	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.28e-05	0.000168	CbGpPWpGaD
Apixaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.22e-05	0.000164	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	2.22e-05	0.000164	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.21e-05	0.000163	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.21e-05	0.000163	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—TYMP—urinary bladder cancer	2.2e-05	0.000162	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.19e-05	0.000161	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—GPX1—urinary bladder cancer	2.18e-05	0.000161	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.18e-05	0.000161	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.15e-05	0.000159	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—ERCC2—urinary bladder cancer	2.14e-05	0.000158	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.13e-05	0.000157	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.13e-05	0.000157	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.12e-05	0.000156	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.03e-05	0.00015	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—MTHFR—urinary bladder cancer	2.01e-05	0.000149	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—RRM2—urinary bladder cancer	2.01e-05	0.000148	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2e-05	0.000147	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—ENO2—urinary bladder cancer	2e-05	0.000147	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.99e-05	0.000147	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	1.98e-05	0.000146	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.95e-05	0.000144	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.94e-05	0.000143	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	1.86e-05	0.000137	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—ENO2—urinary bladder cancer	1.86e-05	0.000137	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.85e-05	0.000137	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—NQO1—urinary bladder cancer	1.85e-05	0.000136	CbGpPWpGaD
Apixaban—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.81e-05	0.000134	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	1.81e-05	0.000133	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.79e-05	0.000132	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.78e-05	0.000131	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.78e-05	0.000131	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.72e-05	0.000127	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.7e-05	0.000125	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.65e-05	0.000122	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.65e-05	0.000122	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PPARG—urinary bladder cancer	1.63e-05	0.00012	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.63e-05	0.00012	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.63e-05	0.00012	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.61e-05	0.000119	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.6e-05	0.000118	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.59e-05	0.000117	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.59e-05	0.000117	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.58e-05	0.000117	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—CREBBP—urinary bladder cancer	1.57e-05	0.000116	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.56e-05	0.000115	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.56e-05	0.000115	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.54e-05	0.000114	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	1.54e-05	0.000114	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.54e-05	0.000113	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.54e-05	0.000113	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.52e-05	0.000112	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NQO1—urinary bladder cancer	1.5e-05	0.000111	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.49e-05	0.00011	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.46e-05	0.000108	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.44e-05	0.000106	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—TYMS—urinary bladder cancer	1.43e-05	0.000106	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	1.41e-05	0.000104	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	1.41e-05	0.000104	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.39e-05	0.000103	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.37e-05	0.000101	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—GPX1—urinary bladder cancer	1.35e-05	9.99e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.34e-05	9.89e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	1.33e-05	9.81e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.33e-05	9.81e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.33e-05	9.79e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PTGS2—urinary bladder cancer	1.29e-05	9.48e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NQO1—urinary bladder cancer	1.28e-05	9.47e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.28e-05	9.42e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.27e-05	9.38e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.26e-05	9.31e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.26e-05	9.31e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	1.25e-05	9.24e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.25e-05	9.22e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.25e-05	9.2e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.25e-05	9.19e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.23e-05	9.09e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.23e-05	9.09e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.23e-05	9.07e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.23e-05	9.07e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.21e-05	8.94e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.21e-05	8.92e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.19e-05	8.79e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.19e-05	8.76e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.18e-05	8.71e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.17e-05	8.63e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—TYMS—urinary bladder cancer	1.16e-05	8.59e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.16e-05	8.55e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	1.15e-05	8.49e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	1.15e-05	8.49e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.12e-05	8.29e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—PTEN—urinary bladder cancer	1.12e-05	8.27e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.12e-05	8.23e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—GPX1—urinary bladder cancer	1.1e-05	8.13e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.09e-05	8.03e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.09e-05	8.01e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	1.08e-05	7.98e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	1.07e-05	7.9e-05	CbGpPWpGaD
Apixaban—ABCG2—Metabolism—EP300—urinary bladder cancer	1.07e-05	7.88e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.04e-05	7.64e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.02e-05	7.51e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.01e-05	7.48e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—TYMS—urinary bladder cancer	9.95e-06	7.34e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NQO1—urinary bladder cancer	9.91e-06	7.31e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	9.84e-06	7.26e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	9.84e-06	7.26e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	9.74e-06	7.18e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—GPX1—urinary bladder cancer	9.42e-06	6.95e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	9.25e-06	6.82e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	9.21e-06	6.79e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PPARG—urinary bladder cancer	9.05e-06	6.67e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PPARG—urinary bladder cancer	8.83e-06	6.51e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	8.7e-06	6.41e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	8.69e-06	6.41e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—CREBBP—urinary bladder cancer	8.49e-06	6.26e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	8.26e-06	6.09e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PPARG—urinary bladder cancer	8.25e-06	6.09e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—PTEN—urinary bladder cancer	8.03e-06	5.92e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	7.98e-06	5.88e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	7.93e-06	5.85e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—TYMS—urinary bladder cancer	7.68e-06	5.67e-05	CbGpPWpGaD
Apixaban—CYP3A5—Metabolism—EP300—urinary bladder cancer	7.66e-06	5.65e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	7.59e-06	5.6e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	7.59e-06	5.6e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—GPX1—urinary bladder cancer	7.27e-06	5.36e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	7.14e-06	5.27e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	7.12e-06	5.25e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PPARG—urinary bladder cancer	7.05e-06	5.2e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—PTEN—urinary bladder cancer	6.96e-06	5.13e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PTGS2—urinary bladder cancer	6.95e-06	5.12e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	6.77e-06	5e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	6.71e-06	4.95e-05	CbGpPWpGaD
Apixaban—CYP2C8—Metabolism—EP300—urinary bladder cancer	6.63e-06	4.89e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	6.49e-06	4.79e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—PTEN—urinary bladder cancer	6.21e-06	4.58e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.06e-06	4.47e-05	CbGpPWpGaD
Apixaban—CYP2C19—Metabolism—EP300—urinary bladder cancer	5.92e-06	4.37e-05	CbGpPWpGaD
Apixaban—ABCB1—Metabolism—EP300—urinary bladder cancer	5.78e-06	4.26e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—PTEN—urinary bladder cancer	5.66e-06	4.18e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	5.55e-06	4.09e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PPARG—urinary bladder cancer	5.44e-06	4.01e-05	CbGpPWpGaD
Apixaban—CYP2C9—Metabolism—EP300—urinary bladder cancer	5.4e-06	3.98e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.23e-06	3.86e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—PTEN—urinary bladder cancer	4.84e-06	3.57e-05	CbGpPWpGaD
Apixaban—CYP1A2—Metabolism—EP300—urinary bladder cancer	4.61e-06	3.4e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.28e-06	3.16e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—PTEN—urinary bladder cancer	3.73e-06	2.75e-05	CbGpPWpGaD
Apixaban—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.56e-06	2.63e-05	CbGpPWpGaD
